Calcitriol and photodynamic therapy of squamous carcinoma, v. 23-Jun-2011 pg. 2 ABSTRACT Photodynamic therapy, mediated by exogenously administered aminolevulinic acid (ALA-PDT) followed by exposure to a laser or broadband light source, is a promising modality for treatment of many types of cancers, but it remains inadequate to treat large, deep solid tumors. Here we report that calcitriol, the active form of Vitamin D3, can be administered prior to ALA as a non-toxic preconditioning regimen to markedly increase the efficacy of ALA-PDT. Using mouse models of squamous skin cancer for preclinical proof of concept, we showed that calcitriol delivered topically or intraperitoneally increased tumoral accumulation of the PDT-activated ALA product protoporphyrin-IX (PpIX) up to 10-fold, mainly by altering expression of the porphyrin synthesis enzymes coproporphyrinogen oxidase (increased) and ferrochelatase (decreased). Calcitriolpretreated tumors underwent enhanced apoptotic cell death following ALA-based PDT.
INTRODUCTION
Photodynamic therapy (PDT) is a cancer treatment that combines a photosensitizer (PS), light, and oxygen to achieve selective cell killing (1, 2) . PDT offers the advantage of dual targeting, since both the PS and the visible light can be effectively localized to the tumor (1) . Excellent selectivity can be achieved with 5-aminolevulinic acid (5-ALA; ALA), a small molecule precursor for the synthesis of endogenous porphyrins, most notably protoporphyrin IX (PpIX) within cells (3) .
Because PpIX is the actual photosensitizer, not ALA, and because pathways that regulate ALA uptake and conversion into PpIX are generally more active in tumor cells than in normal cells, tumor-selective PpIX accumulation to very high levels can be obtained (4) . ALA-PDT has proven clinically useful for wide field treatment of carcinoma in-situ of the skin (4-7) and cervix (8) . ALA-PDT is also useful for image-guided surgical resection of urinary tract dysplasia (9) and high-grade gliomas in the brain (10, 11) . However when employed as a monotherapy, ALA-PDT remains unsatisfactory for large and deep tumors, with incomplete response rates and recurrence rates that are often less than ideal (reviewed in (4)).
To improve the efficacy of ALA-PDT, our goal has been to develop new combination regimens based upon the observation that certain pharmacologic agents, which we call "differentiating agents," can enhance PpIX accumulation in a variety of epithelial cancer cells (12) (13) (14) . For example, we recently reported that methotrexate, administered systemically as a 3-day preconditioning regimen prior to ALA-PDT, significantly enhances the accumulation of PpIX within squamous tumor cell lines in vitro and in vivo (14, 15) . Remarkably, MTX exerts these effects at subnanomolar concentrations (i.e., 100-to 1000-fold lower than those typically used in the clinic (14, 15) , clearly too low to be tumoricidal yet sufficient to trigger differentiation in choriocarcinoma cells (16, 17) , normal keratinocytes (18) , and A431 carcinoma cells (15) . At these same low levels, methotrexate was shown to enhance PpIX accumulation through a mechanism involving increased expression of coproporphyrinogen oxidase (CPO), one of the porphyrin-synthetic enzymes (15) . Author Manuscript Published OnlineFirst on August 1, 2011; DOI: 10.1158/0008-5472. Calcitriol and photodynamic therapy of squamous carcinoma, v. 23-Jun-2011 pg. 4 In the current paper, another class of molecule, Vitamin D, is shown to selectively enhance PDT by preferentially increasing PpIX accumulation in preneoplastic and neoplastic cells in vivo, while causing very little damage to normal tissue. Vitamin D comprises a family of steroid hormones that regulate bone and mineral metabolism, calcium homeostasis, and cellular differentiation; reviewed in (19) (20) (21) . While pathways for synthesis and processing of the various isoforms of Vit D are rather complex, it is clear that the major isoform which interacts with nuclear receptors and mediates hormone effects at the end-organs is the tri-hydroxylated molecule 1α, 25- dihydroxy-vitamin D3 (or calcitriol) (20) . The first indication that Vit D might be useful for enhancing PDT was our finding that calcitriol and synthetic Vit D analogs can stimulate increases in PpIX levels in LNCaP prostate cancer cells (13) . In other cells, however, this phenomenon did not seem entirely consistent. For example, when Vit D was added to cultures of skin keratinocytes, no PpIXelevating effect was observed in monolayer cell culture (22) . However, when the same cells were exposed to calcitriol in a 3-D (organotypic) culture system, they responded by accumulating significantly higher levels of PpIX (22) . The remarkable potency of calcitriol (in the picomolar range)
for stimulating PpIX accumulation in 3-D cultures, coupled with indications that such effects require a native tissue environment, encouraged us to examine Vit D preconditioning in vivo.
Here, we describe an investigation of the ability of Vit D to affect PpIX accumulation in fullyformed epithelial tumors in vivo. Two different tumor models were used to represent premalignant dysplasia and malignant carcinoma, respectively. We confirm that Vit D confers a tumor-specific increase in photosensitizer (protoporphyrin) levels, and demonstrate the underlying mechanism, namely, a change in the expression of two rate-limiting porphyrin-synthetic enzymes. Further, we show that Vit D preconditioning selectively stimulates increased tumor cell killing after ALA-PDT, relative to unconditioned controls. Finally, we explore the mechanism of increased cell death and show that Vit D encourages activation of the extrinsic apoptotic pathway after ALA-PDT, accompanied by massive increases in TNFα production. . Calcitriol and photodynamic therapy of squamous carcinoma, v. 23-Jun-2011 pg. 5
MATERIALS AND METHODS

Chemicals.
Vit D ointments Dovonex® (calcipotriene, 0.005%) and Vectical® (calcitriol, 3 ȝg/g) were obtained from Warner Chilcott Inc. (Rockway, NJ) and Galderma Laboratories (Fort Worth, TX), respectively. Calcitriol (1Į, 25-dihydroxyvitamin D 3 ) was from Sigma-Aldrich (Saint Louis, MO).
Generation of tumor models in vivo.
Superficial tumors in SKH-1 mice were generated by topical application of DMBA and TPA as described (15) . To generate deep subcutaneous tumors, immunocompromised nude mice (Charles River Laboratories) were injected with 2 x 10 6 A431 cells in the flanks, as described (15) .
The A431 human squamous cell carcinoma cell line was purchased from ATCC (American Type Culture Collection; Manassas, VA) where the line was characterized by morphological appearance during growth and recovery, cytochrome C oxidase I PCR for species specificity, and human origin by short tandem repeat (STR) profiling.
Preconditioning regimen using Vitamin D.
Superficial tumors were preconditioned with topical Vectical, Dovonex, or petrolatum (control) once daily for 3 days followed by topical application of ALA (Levulan Kerastick, DUSA Pharmaceuticals, Wilmington, MA) for 4 hours on the fourth day. Deep tumors were preconditioned via systemic Vit D in PBS (1 ȝg/kg) or PBS alone, delivered daily for 3 days by intraperitoneal route. ALA was administered as described (15) .
Analysis of PpIX fluorescence and histological markers in tumors.
For analysis of PpIX levels, tumors were harvested, embedded for frozen sectioning, and analyzed on a Leica confocal microscope as described (15) . Standard hematoxylin-and-eosin staining was done on formalin-fixed/paraffin-embedded tissues, and immunohistochemical staining was performed as described (23 
RESULTS
To test the hypothesis that Vitamin D, delivered as a preconditioning regimen, may enhance the production of intracellular protoporphyrin and subsequent responses to ALA-PDT, two in vivo epithelial tumor models were employed: (i) superficial, low-grade squamous carcinomas (papillomas) generated by chemical carcinogenesis in hairless mice (Fig. 1A) , and (ii) a malignant carcinoma model in which human squamous carcinoma cells (A431) were implanted subcutaneously into immunocompromised nude mice (Fig.1B) . calcitriol or vehicle alone (saline) over a 3-day period. On the fourth day ALA was given intramuscularly, and 24 hr later tumors were harvested and analyzed for PpIX levels (Fig. 1E ).
Calcitriol pretreatment caused a marked increase in PpIX accumulation throughout the tumor (Fig.   1E , compare upper vs. lower panels). A dose-response study (Fig. 1F ) revealed a significant increase in PpIX (4-fold) at a dose of 0.1 μg/kg calcitriol, and PpIX levels reached maximal levels (10-fold) at 0.5 μg/kg calcitriol and above (Fig. 1F) . Local (perilesional) injection of calcitriol into the skin was also effective for delivery (Fig. 1F, bar 7) . Interestingly, intracutaneous injection of calcitriol at a site distant from the tumor also exerted a PpIX-elevating effect, although less pronounced (Fig. 1F, bar 8) . Measurements of the serum calcitriol concentration at 1 hr after injection or topical application revealed calcitriol levels between 6 -9 ng/ml; residual levels at day 4 (after three preconditioning doses) were indistinguishable from normal physiological levels of calcitriol (Supplemental Table 1 ).
Changes in porphyrin synthetic enzyme expression contribute to the increase in PpIX accumulation in Vit D pretreated tumors.
To explore the mechanism of increased PpIX accumulation after calcitriol pretreatment, A431 tumor lysates from mice preconditioned with calcitriol (1 μg/kg) or saline alone were examined for changes in levels of the four porphyrin-synthetic enzymes (ALAD, PBGD, CPO, and FC) that have been described as potentially rate-limiting under various circumstances in different biological systems (24) (25) (26) (27) (28) (29) . Two enzymes were substantially altered after Vit D pretreatment ( Fig.   2A ). Copropopyrinogen oxidase (CPO) was increased ~ 5-fold, and ferrochelatase (FC) was decreased ~4-fold (Fig. 2B) . Each of these changes (higher CPO levels, and lower FC levels) favors an increase in accumulation of PpIX because the enzymes lie immediately upstream and downstream of PpIX, respectively. Calcitriol and photodynamic therapy of squamous carcinoma, v. 23-Jun-2011 pg. 10 
Vitamin D pretreatment elicits preferential changes in cellular differentiation and proliferation within tumors in vivo.
In our previous studies in various epithelial cancer cells in vitro (12) (13) (14) and in vivo (15), we had shown that differentiation-promoting agents such as methotrexate cause an increase in PpIX accumulation that is tightly correlated with the enhancement of terminal differentiation.
Methotrexate always caused growth arrest, but in the case of Vit D, the effects upon growth were less clear. For example, in an organotypic keratinocyte model, calcitriol caused enhanced differentiation while having no apparent effect upon proliferation (22) .
To examine the effects of Vit D upon epithelial tumors in vivo, mice bearing superficial papillomas or deep A431 tumors were preconditioned with Vit D using topical or systemic delivery, respectively, and markers of cellular differentiation (E-cadherin) and proliferation (Ki67) were examined histologically (Fig. 3) . After Vit D pretreatment, E-cadherin expression was increased 4 -6 fold in both types of tumors, compared to an insignificant increase (< 1.5-fold) in normal skin (Fig.   3A ). Vit D pretreatment also increased expression of the proliferative marker (Ki67) in both tumor types, as compared to no significant increase in normal skin (Fig. 3B) . To confirm that Vit D stimulates tumor cell proliferation in vivo, a second assay was performed in which EdU was injected into mice to measure incorporation into newly-synthesized DNA. The latter experiments confirmed that DNA synthesis is stimulated in tumors by pretreatment with Vit D (Fig. 3C) .
To determine which tumor cell populations express the highest levels of PpIX following Vit D pretreatment, colocalization experiments were performed in which adjacent histological sections were examined for PpIX (Supplemental Fig. 1A ), E-cadherin (Supplemental Fig. 1B) , and Ki67 expression (Supplemental Fig. 1C) . The data show that the highest levels of PpIX in the A431 tumors correspond to differentiating areas, and these are almost completely distinct from regions that express the proliferation marker, Ki-67 (Supplemental Fig. 1A-C) . The differentiating tumor areas are also the site of TNFα production following light exposure (Supplemental Fig. 1D ), to be described in more detail below. 
PDT-mediated cell death is enhanced in Vitamin D preconditioned tumors.
Tumors were preconditioned with calcitriol for 3 days, treated with ALA and exposed to light, and then harvested at various time points for analysis of cell death (Fig. 4) . Using the TUNEL assay on A431 tumors, a large increase in cell killing was observed in Vit D pretreated tumors (relative to vehicle alone) at 1, 6 and 24 h, representing an ~6-fold difference between the two conditions at all time points (Fig. 4A, B) . In the squamous papilloma model, a similar preferential enhancement of cell death in Vit D preconditioned tumors was observed (Fig. 4C) . To better examine the microanatomical extent of destruction, tumors were also examined using hematoxylin and eosin (H&E) staining and scored by morphological criteria, primarily the complete loss of cells ( Fig. 4D and Supplemental Fig. 2A,B) . Although evidence of cell death was observable in control tumors by 6 h after ALA-PDT, significantly more areas of cell death were seen by 1 h in Vit Dpreconditioned tumors, rising to a significantly larger fraction of the total tumor area (~250% larger) by 24 hr (Fig. 4E) . Enhancement of cell killing occurred preferentially in Vit D-preconditioned tumor tissue as compared to adjacent normal skin, indicating tumor selectivity of the Vit D effect (Supplemental Fig. 2C ).
Enhancement of PDT-mediated cell death by Vit D involves cleavage of caspase-3 and caspase-8.
Because positive TUNEL labeling indicates (but does not prove) that an apoptotic pathway is activated after ALA-PDT, histological sections from papillomas (Fig. 5A ) or A431 tumors ( pg. 12 precursor form (Fig. 5D) and levels of the cleaved forms, p41 and p43 (Fig. 5E) , were all increased significantly. Together, these results indicate that caspase-8 mediated apoptosis plays a major role in Vit D enhancement of tumor cell death after ALA-PDT.
The combination of Vit D preconditioning and ALA-PDT significantly increases production of TNFα within tumors in vivo.
The fact that caspase-8 is preferentially cleaved in Vit D-preconditioned tumors after ALA-PDT (Fig. 5) suggests that a membrane-associated death receptor, such as TNFR, might be activated in this process. To test this possibility, levels of TNFα in calcitriol-preconditioned tumors were compared to TNFα levels in non-conditioned tumors; a small, < 2-fold increase in the baseline level was observed in the Vit D subset (Fig. 6A) . Following ALA-PDT alone (in the absence of Vit D), a robust increase in TNFα levels of ~10-15 fold was seen at 1 h and remained nearly constant out to 24 h (Fig. 6B and 6C, left side) . In contrast, ALA-PDT delivered after calcitriol preconditioning led to a dramatic and significant increase in TNFα levels, reaching a ~70-fold elevation by 24 h (Fig. 6B and 6C, right side) . Immunostaining of PDT-treated tumor tissue revealed that the highest TNFα expression was found in linear, isolated regions (pockets) near the central portions of the tumors, which appear to represent vascular structures ( Fig. 6D;   Supplemental Fig. 1D ). However, the majority of TNFα staining colocalized within tumor cells that also expressed E-cadherin, i.e., in the differentiated regions of Vit-D preconditioned tumors (Supplemental Fig.1D ). (34, 35) . The extrinsic pathway is involved after PDT, given that caspase-8 and caspase-3 are preferentially activated, whereas caspase-9 and caspase-12 are not.
In the few studies in the literature that examined mechanisms of cell death following aminolevulinate-based PDT, caspase activation in leukemia and lymphoma cells was either undetectable (36) or involved caspase-9 (37). However, human oral (epithelial) cancer cells showed activation of both caspase-8 and caspase-9 after PDT using 5-ALA (38) Calcitriol and photodynamic therapy of squamous carcinoma, v. 23-Jun-2011 pg. 14 Although the ability of Vit D to elevate PpIX levels in cultured cells was described previously (13, 22, 39) (22), and 10-fold in LNCaP prostate carcinoma cells (13) , when those cultures were preincubated with calcitriol (pM to nM concentration range, 24-96 hr incubation) followed by ALA or hexyl-ALA.
The finding that Vit D leads to activation of the extrinsic pathway, and increased TNFα production is particularly compelling because the literature suggests a beneficial link between high TNFα levels and increased PDT efficacy. Bellnier showed that for subcutaneouslyimplanted adenocarcinomas, injection of a single dose of recombinant TNFα at 3 hr prior to PDT (using Photofrin as the photosensitizer) led to an improved tumor response, with no deleterious effects upon normal skin photosensitization (40) . The same group demonstrated that preadministration of 5,6-dimethylxanthenone-4 acetic acid (DMXAA), a drug that elevates TNFα levels, causes significant enhancement in tumor responsiveness to Photofrin-mediated PDT in mice with subcutaneous RIF-1 fibrosarcomas (41). Also, DMXAA displayed a similar PDTenhancing effect using a different tumor model (colon carcinoma cells) and photosensitizer (Photochlor; HPPH) (42) . Although the PS used in those studies was not 5-ALA, the results suggest that any agent capable of increasing intratumoral TNFα levels at the time PDT is administered might help to increase overall cell killing. Preconditioning with Vit D represents a novel way to achieve this end. 
Vit D now joins methotrexate (MTX) in a growing arsenal of agents that effectively promote PpIX accumulation. However, MTX stimulates tumor cell differentiation and inhibits proliferation (15) , whereas Vit D appears to stimulate both differentiation and proliferation (Fig. 3, Fig. 3C ) is actually a well-reported phenomenon (43, 44) whose molecular basis remains controversial. A common misconception is that Vit D always causes epithelial growtharrest, but Gniadecki showed that in human keratinocytes, exposure to calcitriol (at pM or nM concentrations) can cause either growth arrest or hyperproliferation, depending upon whether cells are undifferentiated or committed to terminal differentiation (45) . In breast cancer cell lines (46), calcitriol stimulated cell growth at low concentrations (0.1 nM). In that situation, the balance between proliferation and growth arrest appeared to depend upon levels of a pro-proliferative molecule (a degradation product of calcitriol) that accumulates through the action of an oxidative enzyme, CYP24 (46). Taking everything above into account, the observation that some regions of epithelial tumors in vivo exhibit a pro-proliferative response to calcitriol whereas other regions exhibit a differentiation response appears to make sense.
The more pressing question, of course, is how the differentiated versus proliferative regions of Vit D-pretreated tumors respond to ALA-PDT, and whether the regions with low PpIX could be a problem if surviving cells were to continue to proliferate after treatment. Our data showed a robust cell kill in the central zone of nodular tumors ( Supplemental Fig 2) , consistent with a combined effect of ALA-PDT and hypoxia in these regions. However, the surviving rim of cells observed at the tumor periphery is a reminder that this report is only an initial description of Vit D and ALA-PDT; no judgment about preclinical efficacy can be made until detailed animal studies are (50); (iii) a single application of calcitriol ointment. We found that peak levels were similar for all conditions (6 -9 ng/ml), within the range reported by Muindi et al. (50) . No evidence for a residual calcitriol elevation was found, i.e., the serum trough levels after 3 days of preconditioning were indistinguishable from physiological background levels in mice (50) . This suggests a reasonable safety margin, given that Muindi et al. (50) employed calcitriol doses at least 8 times higher than our study, and the doses used were sufficient to exert antitumor effects without any detectable side effects in mice (50 
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